---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-002368"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:40:32.322592+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Crinetics PALSONIFY Q4 net revenue >$5M; atumelnant Phase 2 CAH shows 67% A4 reduction

## Summary
- Unaudited Q4 2025 PALSONIFY net product revenue exceeded $5.0M, with >200 enrollment forms and >125 unique prescribers.
- Atumelnant 80mg in CAH cohort 4: 67% mean reduction in androstenedione, 88% of patients achieved physiologic glucocorticoid doses.
- No serious adverse events or hepatic transaminase AEs in cohort 4 or open-label extension (25 patients, >750 weeks cumulative exposure).
- About half of new PALSONIFY bottles reimbursed without Quickstart bridge; 12-month prior authorizations typical.
- Crinetics hosts investor call today 8:30 AM ET to discuss results and outlook.

## SEC filing metadata
- accession: 0001193125-26-002368
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/0001193125-26-002368-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312526002368/d86003d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-002368
- JSON: https://secwatch.observer/filing/0001193125-26-002368.json
- Plain text: https://secwatch.observer/filing/0001193125-26-002368.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.